These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35056426)

  • 1. Risk Factors for Therapeutic Intervention of Remdesivir in Mild to Moderate COVID-19-A Single-Center Retrospective Study of the COVID-19 Fourth Pandemic Period in Wakayama, Japan.
    Tamura S; Kaki T; Niwa M; Yamano Y; Kawai S; Yamashita Y; Tanaka H; Saito Y; Kajimoto Y; Koizumi Y; Yamaue H; Nakao N; Nojiri T; Hironishi M
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056426
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan.
    Tsuzuki S; Hayakawa K; Uemura Y; Shinozaki T; Matsunaga N; Terada M; Suzuki S; Asai Y; Kitajima K; Saito S; Yamada G; Shibata T; Kondo M; Izumi K; Hojo M; Mizoue T; Yokota K; Nakamura-Uchiyama F; Saito F; Sugiura W; Ohmagari N
    Int J Infect Dis; 2022 May; 118():119-125. PubMed ID: 35192953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
    Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
    PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Administration of Remdesivir and Intensive Care Unit Admission in Hospitalized Pregnant Individuals With Coronavirus Disease 2019 (COVID-19).
    Eid J; Abdelwahab M; Colburn N; Day S; Cackovic M; Rood KM; Costantine MM
    Obstet Gynecol; 2022 Apr; 139(4):619-621. PubMed ID: 35134032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19.
    Finn A; Jindal A; Andrea SB; Selvaraj V; Dapaah-Afriyie K
    Am J Med Sci; 2022 May; 363(5):403-410. PubMed ID: 35151637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
    JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19).
    Wong CKH; Lau KTK; Au ICH; Xiong X; Lau EHY; Cowling BJ
    Clin Infect Dis; 2022 Apr; 74(8):1450-1458. PubMed ID: 34265054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city.
    Jeck J; Jakobs F; Kron A; Cornely OA; Kron F
    J Antimicrob Chemother; 2022 Feb; 77(3):753-757. PubMed ID: 34849943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19.
    Falcone M; Suardi LR; Tiseo G; Barbieri C; Giusti L; Galfo V; Forniti A; Caroselli C; Della Sala L; Tempini S; Okoye C; Monzani F; Menichetti F
    Clin Ther; 2022 Mar; 44(3):364-373. PubMed ID: 35120742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
    Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
    CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
    Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
    Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Safety of Remdesivir among Hospitalised Adult Patients with RT PCR Confirmed COVID 19 Requiring ICU Care in Kalyana Karnataka.
    Waddankeri S; Hesarur SS; Hiremath SS; A S; Ar S; Raikod BP; Kinagi S; Biradar S; Belli B; Melkundi S; Singh G
    J Assoc Physicians India; 2021 Aug; 69(8):11-12. PubMed ID: 34472806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital.
    Jeck J; Jakobs F; Kron A; Franz J; Cornely OA; Kron F
    Infection; 2022 Feb; 50(1):191-201. PubMed ID: 34406606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study.
    Boglione L; Dodaro V; Meli G; Rostagno R; Poletti F; Moglia R; Bianchi B; Esposito M; Borrè S
    J Med Virol; 2022 Aug; 94(8):3653-3660. PubMed ID: 35411627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
    Olender SA; Perez KK; Go AS; Balani B; Price-Haywood EG; Shah NS; Wang S; Walunas TL; Swaminathan S; Slim J; Chin B; De Wit S; Ali SM; Soriano Viladomiu A; Robinson P; Gottlieb RL; Tsang TYO; Lee IH; Hu H; Haubrich RH; Chokkalingam AP; Lin L; Zhong L; Bekele BN; Mera-Giler R; Phulpin C; Edgar H; Gallant J; Diaz-Cuervo H; Smith LE; Osinusi AO; Brainard DM; Bernardino JI;
    Clin Infect Dis; 2021 Dec; 73(11):e4166-e4174. PubMed ID: 32706859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.